Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06673017 · ClinicalTrials.gov registry record · Phase 1
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
A Phase 1 study of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by PanTher Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
- 6
- Study locations
NCT06673017 is a Phase 1 study of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by PanTher Therapeutics. The registered enrollment target is 26 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (93% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT06673017, a Phase 1 study of Pancreatic Cancer and Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by PanTher Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naïve subjects with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC).
Conditions Studied
Interventions
- DRUG PTM-101
Study Locations (6)
Texas
- University of Texas Southwestern Medical Center - Dallas
- The University of Texas MD Anderson Cancer Center - Houston
California
- Hoag Memorial Hospital Presbyterian - Newport Beach
Michigan
- Karmanos Cancer Institute - Detroit
New York
- Northwell Health Zuckerberg Cancer Center - Lake Success
Washington
- Virginia Mason Medical Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2025-04-14 |
| Est. Completion | 2028-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06673017
The ClinicalTrials.gov registry entry for NCT06673017 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (93% lower). The listed sponsor is PanTher Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which PTM-101 is the first listed.
NCT06673017 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Texas, California, Michigan.
Frequently Asked Questions
What is clinical trial NCT06673017 about?
NCT06673017 is a clinical study titled "PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)". This is a multi-center, non-randomized, single-arm, open-label, phase Ib, dose escalation/dose expansion study of PTM-101 when combined with neoadjuvant chemotherapy for the treatment of treatment-naïve subjects with borderline resectable and locally advanced pancreatic ductal adenocarcinoma (PDAC).
What is the current status of trial NCT06673017?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2025-04-14. Estimated completion is 2028-06.
What conditions does trial NCT06673017 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT06673017?
The interventions under investigation include: PTM-101 (DRUG).
Who is sponsoring clinical trial NCT06673017?
This trial is sponsored by PanTher Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06673017 being conducted?
This trial has 6 study locations across California, Michigan, New York, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.